Sanofi (SNY) Q2 FY2026 6-K Filings and Company Events

Filings that contain financial statements

Sanofi is a foreign private issuer and furnishes interim results on Form 6-K rather than a 10-Q.

• Form 6-K filed 2026-07-30, accession 0001628280-26-050803 – Half-Year Financial Report 2026 (Exhibit 99.2) for the six months ended June 30, 2026, with the half-year management report and condensed consolidated IFRS financial statements: income statement, statement of comprehensive income, balance sheet, cash flow statement, statement of changes in equity, and notes (including litigation, acquisitions and net debt). The same filing carries the XBRL financial data for the period.
• Form 6-K filed 2026-07-30, accession 0001121404-26-000008 – Q2 2026 results press release (Exhibit 99.1) covering the three months and six months ended June 30, 2026: net sales by geography and product, business income statement (Appendix 3), IFRS-to-business net income reconciliation (Appendix 4), change in net debt and summarised cash flow (Appendix 5). Figures are the company's unaudited results; the full IFRS statements are in accession 0001628280-26-050803.

• Form 6-K filed 2026-04-23, accession 0001121404-26-000004 – Q1 2026 results press release for the three months ended March 31, 2026.

No other 6-K in the period carries financial statements. The remaining 6-Ks are press releases on approvals, pipeline, governance and transactions.

Q2 2026 results and guidance upgrade (6-K, July 30, 2026; accession 0001121404-26-000008)

• Q2 net sales were $13.49 billion, up 17.8% at constant exchange rates (16.0% at actual rates). Six-month net sales were $25.79 billion, up 15.7% (11.1% at actual rates). US sales grew 33.5% in the quarter; Europe grew 1.3%; Rest of World grew 3.7% (China down 4.9%).
• Dupixent sales were $5.99 billion in the quarter, up 37.6%, the first quarter above 5 billion euros (about $5.82 billion at the Q2 2026 average rate). Pharma launches (including Ayvakit, ALTUVIIIO and Sarclisa) were $1.52 billion, up 48.3%. Vaccines were $1.34 billion, down 4.7%, against a high influenza comparison base.
• Business operating income was $3.83 billion, up 35.8%; business net income was $2.91 billion; business EPS was 2.09 euros ($2.43) per ordinary share, or $1.22 per ADS (one ADS = one half share), up 33.3%.
• IFRS net income was $398.91 million, down 91.3% from a year earlier (in euros at actual rates; the release gives no constant-rate figure), reflecting a $1.20 billion intangible impairment charge in the quarter, of which $1.11 billion related to the amlitelimab asset, and the absence of the net income from discontinued operations (Opella) included in the year-earlier quarter. Free cash flow was $3.11 billion in the quarter and $4.34 billion for six months.
• Guidance upgraded: 2026 sales are now expected to grow around 10% at constant exchange rates, with business EPS at constant rates growing slightly faster than sales. The release estimates currency effects at about -1% on sales and -2% on business EPS. The company also stated that it expects Dupixent sales of about $28.80 billion (25 billion euros) in 2030 and about $11.52 billion (10 billion euros) from Pharma launches, both at constant rates.
• Net debt was $17.71 billion at June 30, 2026. The increase from January 1 reflected the Dynavax acquisition, the share buyback, the dividend and the net payment related to Opella.
• Next results: Q3 2026 on October 30, 2026.

M&A and partnerships

• Dynavax Technologies – closed. The half-year report states Sanofi "finalized the acquisition" of Dynavax on February 10, 2026, through a cash tender offer at $15.50 per share, a fully diluted equity value of about $2.2 billion (including repayment of short-term debt of $0.3 billion). The deal brings the marketed adult hepatitis B vaccine Heplisav-B and a shingles vaccine candidate. Heplisav-B contributes to US vaccine sales from the first quarter. Sources: accession 0001628280-26-050803 and 6-K accession 0001193125-26-043830, filed 2026-02-10, whose Exhibit 99.1 is headed "Sanofi completes the acquisition of Dynavax" (Paris, February 10, 2026).
• Regeneron – expanded collaboration, signed (6-K, October 1, 2026; accession 0001193125-26-410232). Sanofi and Regeneron expanded their antibody Alliance to add four long-acting Regeneron-invented antibodies (IL-13, IL-4xIL-13 bispecific, IL-4, IL-4Rα). Regeneron receives $1 billion upfront, with up to $7 billion more in development, regulatory and commercial milestones; development and commercialisation costs and future profits are shared 50:50. The existing Dupixent profit-sharing arrangement is unchanged. Regeneron may opt in to Sanofi's lunsekimig after phase 3 studies in COPD. The companies state they have settled their prior collaboration-related litigation.
• Cheplapharm – announced intention, not closed (6-K, September 17, 2026; accession 0001193125-26-393653; press release dated September 14, 2026). Cheplapharm would take over 20 mature medicines (including Lovenox outside the US) and three manufacturing sites (Hungary, Singapore, France) in exchange for a 26.4% equity stake in Cheplapharm. Commercial transfer is planned to begin in the first quarter of 2027, with full completion expected by the third quarter of 2027, subject to employee consultation, regulatory approvals and customary conditions. Sanofi says there is no expected impact on 2026 guidance; further financial detail is to follow.

Capital actions

• Bond issue (6-K, April 29, 2026; accession 0001193125-26-188783). Sanofi priced 2.3 billion euros ($2.70 billion) of notes in three tranches under its Euro Medium Term Note programme: 1,000 million euros ($1.17 billion) at 3.000% due May 2029; 650 million euros ($761.67 million) at 3.375% due May 2033; 650 million euros ($761.67 million) at 3.750% due May 2037.
• Share buyback. The 1 billion euro ($1.17 billion) buyback for cancellation was completed in April 2026 (accession 0001121404-26-000008).
• Dividend (6-K, May 5, 2026; accession 0001193125-26-204946). Shareholders at the April 29, 2026 meeting approved an ordinary dividend of 4.12 euros ($4.82) per ordinary share for 2025, paid May 7, 2026, the 31st consecutive annual increase.
• Employee share plan (6-K, June 12, 2026; accession 0001193125-26-268874). The 2026 employee stock purchase plan opened June 9 at a subscription price of 59.87 euros ($69.62) per share, up to 9,816,701 shares.

Management and governance

• CEO transition (6-K, May 5, 2026; accession 0001193125-26-204946). At the April 29, 2026 general meeting Belén Garijo was appointed to the board and became Chief Executive Officer on May 1, 2026. Christel Heydemann joined the board as an independent director; Frédéric Oudéa chairs the board.
• R&D head (6-K, June 24, 2026; accession 0001193125-26-280319). Paulo Fontoura was named Executive Vice President, Global Head of R&D Pharma, effective September 1, 2026, succeeding Houman Ashrafian.
• Executive Committee reshuffle (6-K, July 27, 2026; accession 0001193125-26-316771). Effective September 1, 2026: François Roger leads Finance, now including Global Partnering and Business Development; Thomas Grenier becomes head of General Medicines, replacing Olivier Charmeil (who moves to a strategic advisory role); General Counsel Roy Papatheodorou is leaving, with Jamie Haney named General Counsel; Thomas Triomphe adds responsibility for China.

Pipeline decisions and setbacks

• Lunsekimig phase 2 readout (6-K filed 2026-04-15; accession 0001193125-26-155930). AIRCULES in asthma and DUET in CRSwNP met primary and key secondary endpoints; the exploratory VELVET phase 2b study in atopic dermatitis did not meet its primary endpoint, though key secondary skin-clearance endpoints improved (April 7). Lunsekimig is the asset Regeneron can opt into under the October 1 expansion.

• Amlitelimab discontinued in atopic dermatitis (6-K, July 27, 2026; accession 0001193125-26-316771). Sanofi will not submit amlitelimab for global regulatory review, saying the evidence does not support a meaningful improvement over standard of care. 2026 guidance was not amended at that time. The Q2 results record the related impairment of the asset.
• Q2 results also record the discontinuation of itepekimab (COPD and chronic rhinosinusitis, with Regeneron) and balinatunfib (phase 2 Crohn's disease and ulcerative colitis) (accession 0001121404-26-000008).
• Riliprubart MOBILIZE phase 3 stopped (6-K, June 12, 2026; accession 0001193125-26-268874). An interim analysis found the study in refractory CIDP unlikely to show sufficient efficacy; no significant financial cost, and 2026 guidance unchanged. The VITALIZE study continues.
• Dupixent in lichen simplex chronicus: both phase 3 studies missed their primary endpoints (accession 0001121404-26-000008).

Regulatory approvals and positive data

• Cenrifki (tolebrutinib) approved in the EU for non-relapsing secondary progressive multiple sclerosis, June 23, 2026 (accession 0001193125-26-280319). The label carries a drug-induced liver injury warning.
• Tzield approved in the US (accelerated approval) for children aged 8 to 17 with recently diagnosed stage 3 type 1 diabetes, June 13, 2026 (accession 0001193125-26-276766).
• Subcutaneous Sarclisa approved in the EU (June 8), Japan (June 19) and the US (as Sarclisa Escena via on-body injector, July 10, 2026) (accessions 0001193125-26-268874, 0001193125-26-280319, 0001193125-26-306689).
• Wayrilz approved in Japan for immune thrombocytopenia, June 23, 2026 (accession 0001193125-26-280319).
• MenQuadfi approved in the EU for infants from six weeks, August 4, 2026 (accession 0001193125-26-336497).
• Nexviazyme met its primary endpoint in the phase 3 Baby-COMET study in infantile-onset Pompe disease; a US submission is expected in the second half of 2026 (accession 0001193125-26-296990).
• Venglustat accepted for FDA priority review in type 3 Gaucher disease; target action date November 25, 2026 (accession 0001193125-26-260613).
• Efdoralprin alfa beat standard-of-care augmentation therapy on functional AAT levels in a phase 2 study in alpha-1 antitrypsin deficiency (accession 0001193125-26-240810).

Legal

The half-year report's litigation note (accession 0001628280-26-050803) states that a decision from the Eleventh Circuit on the Zantac federal multi-district litigation appeal is expected in the second half of 2026. Talc litigation in the US is also described there.

Not reflected

The 2026 Q3 results (due October 30, 2026) are not yet filed. Financial terms of the Cheplapharm transaction have not been disclosed.